Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 12

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
 upon settlement
of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded
derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any
unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the
associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the
Black-Scholes pricing model and a derivative liability of $1,820,106was recognized by the Company as of December 31,, 2024.

Derivative Liability consisted of the following :

SCHEDULE
OF DERIVATIVE LIABILITY

                                        As of      As of                              
                            December 31, 2024      September 30, 2024                 
  Lender 1                           $796,586                                802,337  
  Lender 4                           $199,147                                200,584  
  Lender 5                           $398,293                                401,168  
  Lender 6                           $353,535                                      -  
  Lender 7                            $72,545                                      -  
  Total                            $1,820,106      $                       1,404,090  
  Derivative liability             $1,820,106      $                       1,404,090  

9. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company
contains the following classes of capital stock as of December 31, 2024:

Common stock, $0.0001par value; 5,800,000,000shares
authorized: 21,554,704shares issued and outstanding.

With respect to each matter submitted to a vote of
stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the
number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution
or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the
Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001par value,800,000,000shares
authorized of which600,000is designated as Series AA Preferred Stock: 34shares issued and outstanding as of December 31